Content within this site is for medical journalists outside the U.S. only.
For requests regarding Lyxumia® (lixisenatide):*
Philip McNamara Tel: +1 908 981 5497 Mobile: + 1 908 210 4047 E-mail: Philip.McNamara@sanofi.comFor requests within the U.S.:
Susan Brooks Tel: +1 908 987 6566 Mobile: +1 201 572 4994 E-mail: Susan.Brooks@sanofi.com*Lyxumia® (lixisenatide), a glucagon-like peptide-1 receptor agonist (GLP-1 RA), is approved in Europe, Mexico, Australia, Japan, Brazil, Colombia and Chile for the treatment of patients with type 2 diabetes mellitus. Lyxumia is the proprietary name approved by the European Medicines Agency and other health authorities for the GLP-1 RA lixisenatide.
SUIVEZ-NOUS